(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Discovery of massive spider's web in Greece reveals unexpected behavior - 220-year-old who threatened German train attack remanded in custody
- 3Artemis II live updates: NASA's moon mission breaks Apollo record for farthest distance humans have traveled from Earth
- 4Qatar LNG Ships U-Turn After Attempt to Pass Through Hormuz
- 521 Incredibly Entertaining Contemplations To Observe Consistently
- This Week In Space podcast: Episode 187 — An Inspired Enterprise
- Colombia's military rescues 6 siblings who hid in the rainforest to escape from a rebel group
- Figure out What Shift Differentials Mean for Your General Attendant Compensation
- Nurturing Hacks: Astuteness from Experienced Mothers and Fathers
- Man threatens attack on German high-speed train, injures several
- Major railway disruptions persist as Germany braces for more snow
- 7 Strange Devices to Make Your Party Stick Out!
- More loons are filling Maine's lakes with their ghostlike calls
- Sally Rooney books may be withdrawn from UK sale over Palestine Action ban, court told
